Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib (REGORA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02800330
Recruitment Status : Completed
First Posted : June 15, 2016
Last Update Posted : August 2, 2018
Sponsor:
Information provided by (Responsible Party):
Prof. R.H.J. Mathijssen, MD, PhD, Erasmus Medical Center

Brief Summary:
Regorafenib is a novel oral multi-kinase inhibitor which targets angiogenic, stromal and oncogenic receptor tyrosine kinases. It is currently registered for GIST and mCRC. When regorafenib is co-administered with an acid suppressive agent, the intra-gastric pH increases, and as a result the equilibrium of ionized/non-ionized regorafenib may shift to the less soluble non-ionized form which reduces regorafenib bioavailability and exposure. Since proton pump inhibitors (PPIs) are often used during regorafenib therapy, this drug-drug interaction (DDI) confronts pharmacists and oncologists with challenges in clinical practice. In this study the investigators will therefore evaluate the impact of PPI-induced intra-gastric pH elevation on regorafenib pharmacokinetics in patients with GIST and mCRC.

Condition or disease Intervention/treatment Phase
Colorectal Neoplasms Gastrointestinal Stromal Tumors Drug: Esomeprazole 40mg concomitantly Drug: Esomeprazole 40mg before Drug: Regorafenib 160mg or 120mg Phase 4

Detailed Description:
Patients will start with regorafenib in a loading phase of 21 days and will be admitted for 24 hours to the hospital for pharmacokinetic blood sampling on day 21, 49 and 77 (± 1-2 days). Patients will be randomized into 2 sequence groups (respectively sequences phase A-B-C or phase C-B-A). The patient will use regorafenib alone (phase A) or with esomeprazole for five days (phases B and C). To (completely) rule out a pH-dependent DDI between regorafenib and esomeprazole, during phase B of the study regorafenib is given concomitantly for five days, while during phase C regorafenib is given 3 hours after esomeprazole intake for five days (when the intragastric pH is maximally elevated by esomeprazole).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) or Gastrointestinal Stromal Tumour (GIST)
Study Start Date : May 2016
Actual Primary Completion Date : February 2018
Actual Study Completion Date : February 2018


Arm Intervention/treatment
Arm A (e.g. sequence phase A-B-C)
In this arm patients will use regorafenib alone in the first cycle (treatment A), then regorafenib with esomeprazole concomitantly in the second cycle (treatment B) and at last they will use regorafenib with esomeprazole 3 hours before (treatment C)
Drug: Esomeprazole 40mg concomitantly
During phase B the patients will use esomeprazole 40mg concomitantly with regorafenib for 5 days.
Other Name: phase B

Drug: Esomeprazole 40mg before
During phase C the patients will use esomeprazole 40mg 3 hours before regorafenib for 5 days.
Other Name: phase C

Drug: Regorafenib 160mg or 120mg
Patients will use regorafenib 160mg or 120mg during all phases (A, B, C)

Arm B (e.q. sequence phase C-B-A)
In this arm patients will use regorafenib with esomeprazole 3 hours before (treatment C), then regorafenib with esomeprazole concomitantly in the second cycle (treatment B) and at last they will use regorafenib alone (treatment A),
Drug: Esomeprazole 40mg concomitantly
During phase B the patients will use esomeprazole 40mg concomitantly with regorafenib for 5 days.
Other Name: phase B

Drug: Esomeprazole 40mg before
During phase C the patients will use esomeprazole 40mg 3 hours before regorafenib for 5 days.
Other Name: phase C

Drug: Regorafenib 160mg or 120mg
Patients will use regorafenib 160mg or 120mg during all phases (A, B, C)




Primary Outcome Measures :
  1. As primary endpoint, AUC of regorafenib alone and AUC of regorafenib with esomeprazole (concomitantly and 3 hours before regorafenib intake, respectively) will be related. [ Time Frame: T=0, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h, 24h at day 21, day 49 and day 77 ]
    The AUC of regorafenib will be determined by multiple blood samples at T=0, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h, 24h at day 21, day 49 and day 77


Secondary Outcome Measures :
  1. The Cmax of regorafenib alone and regorafenib with esomeprazole (concomitantly and 3 hours before regorafenib intake respectively) will be related [ Time Frame: T=0, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h, 24h at day 21, day 49 and day 77 ]
    The Cmax of regorafenib will be determined by multiple blood samples at T=0, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h, 24h at day 21, day 49 and day 77

  2. Number of participants with treatment related adverse events as assessed by CTCAE v4.0 in absence and presence of esomeprazole [ Time Frame: Through study completion, approximately 0.5 year ]
  3. The Tmax of regorafenib alone and regorafenib with esomeprazole (concomitantly and 3 hours before regorafenib intake respectively) will be related [ Time Frame: T=0, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h, 24h at day 21, day 49 and day 77 ]
    The Tmax of regorafenib will be determined by multiple blood samples at T=0, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h, 24h at day 21, day 49 and day 77

  4. The clearance of regorafenib alone and regorafenib with esomeprazole (concomitantly and 3 hours before regorafenib intake respectively) will be related [ Time Frame: T=0, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h, 24h at day 21, day 49 and day 77 ]
    The clearance of regorafenib will be determined by multiple blood samples at T=0, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h, 24h at day 21, day 49 and day 77



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Histological or cytological confirmed diagnosis of mCRC or GIST and prior treatment specific:

    1. mCRC-patients who have been previously treated with, or are not considered candidates for, available therapies according to common practice.
    2. Irresectable or metastatic GIST who progressed on or are intolerant to prior treatment with imatinib and sunitinib.
  3. ECOG Performance Status ≤ 1
  4. Able and willing to sign the Informed Consent Form
  5. No concurrent (over the counter) use of other acid reducing drugs (PPIs, H2As and/or antacids), other than esomeprazole 40mg once daily during the study.
  6. No concurrent medication or supplements which can interact with esomeprazole or regorafenib during the study period.
  7. Abstain from grapefruit, grapefruit juice, herbal dietary supplements, and herbal tea during the study period.
  8. Adequate baseline patient characteristics (complete blood count, and serum biochemistry which involves sodium, potassium, creatinin, calculation of creatinin clearance (MDRD), AST, ALT, gamma glutamyl transpeptidase, lipase, lactate dehydrogenase, ALP, total bilirubin, albumin, glucose, INR, thyroid function tests, and PTT or APTT within two weeks prior to the study).

Exclusion Criteria:

  1. Pregnant or lactating patients.
  2. Patients with known impaired drug absorption (e.g. gastrectomy and achlorhydria).
  3. Known serious illness or medical unstable conditions that could interfere with this study; requiring treatment (e.g. infection, bleedings, uncontrolled hypertension despite optimal medical management, HIV, hepatitis, organ transplants, kidney, cardiac and respiratory diseases).
  4. Non-healing wound, non-healing ulcer, or non-healing bone fracture
  5. Major surgical procedure or significant traumatic injury within 28 days before start of study medication.
  6. Patients with evidence or history of any bleeding diathesis, irrespective of severity
  7. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of study medication.
  8. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 month before the start of study medication (except for adequately treated catheter-related venous thrombosis occurring more than one month before the start of study medication)
  9. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months)
  10. Myocardial infarction less than 6 months before start of study drug.
  11. Uncontrolled cardiac arrhythmias
  12. Symptomatic CNS metastases or history of psychiatric disorder that would prohibit the understanding and giving of informed consent.
  13. Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
  14. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation.
  15. Known history of HIV infection, active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy.
  16. Patients on strong CYP3A4 inhibitors or inducers are not eligible for the study (see appendix B).
  17. The use of BCRP or P-glycoprotein substrates which leads to a clinically relevant drug-drug interaction concerning the pharmacokinetics of regorafenib.
  18. Unwillingness to abstain from grapefruit (juice), (herbal) dietary supplements, herbals, over-the-counter medication (except for paracetamol and ibuprofen) and other drugs known to seriously interact with esomeprazole and regorafenib during the study period.
  19. Unwillingness to abstain from acid beverages such as orange juice and other acidic beverages (e.g. Coca-Cola, 7-UP etc.) in the morning (between 06.00-14.00u AM) during regorafenib treatment in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02800330


Locations
Layout table for location information
Netherlands
Erasmus Medical Center
Rotterdam, South Holland, Netherlands, 3015 CE
Sponsors and Collaborators
Erasmus Medical Center
Investigators
Layout table for investigator information
Principal Investigator: R.H.J. Mathijssen, MD, PhD EMC

Layout table for additonal information
Responsible Party: Prof. R.H.J. Mathijssen, MD, PhD, Prof, MD, PhD, Erasmus Medical Center
ClinicalTrials.gov Identifier: NCT02800330     History of Changes
Other Study ID Numbers: EMC16-165
First Posted: June 15, 2016    Key Record Dates
Last Update Posted: August 2, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastrointestinal Stromal Tumors
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Esomeprazole
Proton Pump Inhibitors
Anti-Ulcer Agents
Gastrointestinal Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action